T-Knife Therapeutics

T-Knife Therapeutics is a private, pre-clinical stage biotech company pioneering next-generation TCR-T cell therapies for solid tumors. Its core differentiation lies in the proprietary MyT™ platform, which generates fully human, high-affinity TCRs, combined with internally developed enhancements like novel CD8 coreceptors and switch receptors. The company's lead candidate, TK-6302, targeting the PRAME antigen, is planned to enter Phase 1 trials in 2026, positioning T-Knife in the competitive but high-potential field of engineered cell therapies for oncology. With seasoned leadership and strong academic roots from the Max Delbrück Center and Charité in Berlin, T-Knife is advancing a pipeline aimed at addressing high unmet medical needs.

Proprietary MyT™ platform for discovering fully human, high-affinity T cell receptors (TCRs) combined with synthetic biology capabilities to engineer novel CD8 coreceptors and switch receptors designed to enhance T cell fitness, persistence, and overcome the immunosuppressive tumor microenvironment.

T-Knife operates in the highly competitive TCR-T cell therapy space, competing with public companies like Adaptimmune and Immunocore (with an approved TCR-based therapy), as well as numerous private biotechs and large pharma partners. Differentiation hinges on the claimed advantages of its fully human MyT™ platform and its suite of synthetic biology enhancements designed for superior T cell performance in solid tumors.